PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsMechlorethamine
Mustargen, Ledaga(mechlorethamine)
Ledaga, Valchlor (mechlorethamine) is a small molecule pharmaceutical. Mechlorethamine was first approved as Mustargen on 1982-01-01. It is used to treat hodgkin disease, malignant pleural effusion, mycosis fungoides, and neoplasm metastasis in the USA. It has been approved in Europe to treat mycosis fungoides.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
respiratory tract diseasesD012140
hemic and lymphatic diseasesD006425
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Valchlor (discontinued: Mustargen)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mechlorethamine hydrochloride
Tradename
Company
Number
Date
Products
VALCHLORHelsinn Birex PharmaceuticalsN-202317 RX2013-08-23
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
valchlorNew Drug Application2024-11-20
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hodgkin disease—D006689C81
mycosis fungoides—D009182C84.0
neoplasm metastasisEFO_0009708D009362—
malignant pleural effusion—D016066J91.0
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Mechlorethamine Hydrochloride, Valchlor, Helsinn
78720502029-07-08U-1427
78385642026-03-07DP
84503752026-03-07DP
85018182026-03-07DP
85018192026-03-07U-1427
93821912026-03-07DP
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01A: Alkylating agents
— L01AA: Nitrogen mustard analogues
— L01AA05: Chlormethine
HCPCS
Code
Description
J9230
Injection, mechlorethamine hydrochloride, (nitrogen mustard), 10 mg
Clinical
Clinical Trials
4856 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple myelomaD009101—C90.0—1———1
Plasma cell neoplasmsD054219———1———1
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MycosesD009181—B35-B49————33
Mycosis fungoidesD009182—C84.0————33
T-cell lymphomaD016399——————11
T-cell lymphoma peripheralD016411——————11
T-cell lymphoma cutaneousD016410—C84.A————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMechlorethamine
INNchlormethine
Description
Mechlorethamine is a nitrogen mustard and an organochlorine compound. It has a role as an alkylating agent.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CN(CCCl)CCCl
Identifiers
PDB—
CAS-ID51-75-2
RxCUI—
ChEMBL IDCHEMBL427
ChEBI ID28925
PubChem CID4033
DrugBankDB00888
UNII ID50D9XSG0VR (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 8,392 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2,807 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use